Inhibitory effects of incadronate on the progression of rat experimental periodontitis by Porphyromonas gingivalis infection

Journal of Periodontology

Volumn 74, Issue 5, 2003, Pages 603-609

  Tani Ishii, Nobuyuki ^a   Minamida, Genshi ^a   Saitoh, Daisuke ^a   Chieda, Keiko ^a   Omuro, Hiromasa ^a   Sugaya, Akira ^a   Hamada, Nobushiro ^a   Takahashi, Yusuke ^a   Kiyohara, Shiro ^a   Kashima, Isamu ^a   Teranaka, Toshio ^a   Umemoto, Toshio ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

Animal studies; Bisphosphonates therapeutic use; Bone resorption prevention and control; Incadronate therapeutic use; Neutrophils; Periodontal ligament pathology; Periodontitis prevention and control; Porphyromonas gingivalis

Indexed keywords

INCADRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERAL; CELL MIGRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTAL INFECTION; FEMALE; GINGIVA; HISTOPATHOLOGY; INFLAMMATORY CELL; INOCULATION; MORPHOMETRICS; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOLYSIS; PERIODONTAL LIGAMENT; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; RAT; TOOTH RADIOGRAPHY;

ALVEOLAR BONE LOSS; ANALYSIS OF VARIANCE; ANIMALS; BACTEROIDACEAE INFECTIONS; BONE DENSITY; CELL MOVEMENT; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; NEUTROPHILS; PERIODONTAL LIGAMENT; PERIODONTITIS; PLACEBOS; PORPHYROMONAS GINGIVALIS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0038515250     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2003.74.5.603     Document Type: Article

References (27)

1. Altman RD, Johnston CC, Khairi MR. Wellman H, Serafini AN, Sankey RR. Influence of sodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). New Engl J Med 1973;289: 1379-1384.
2. Russell RG, Smith R, Preston CJ, Walton RS, Woods CG. Diphosphonates in Paget's disease. Lancet 1974;1:894-898.
3. Shipman CM, Croucher PI, Graham R, Russell G, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-5297.
4. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 1991;42:919-944.
5. Fleisch H. Prospective use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 1993;76:1397-1398.
6. Weinreb M, Quartuccio H, Seedor JG, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res 1994;29:35-40.
7. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-830.
8. Reddy MS, Weatherford TW 3rd, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol 1995;66:211-217.
9. Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 1995;30:277-284.
10. Llavaneras A, Ramamurthy NS, Heikkila P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats. J Periodontol 2001;72: 1069-1077.
11. Nishikawa M, Yamamoto M, Murakami et al. A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res 1998;13:986-995.
12. O'uchi N, Nishikawa H, Yoshino T, et al. Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs. J Periodont Res 1998;33:196-204.
13. Baker PJ, Evans RT, Roopenian DC. Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch Oral Biol 1994;39:1035-1040.
14. Baker PJ, Carter S, Dixon M, Evans RT, Roopenian DC. Serum antibody response to oral infection precedes but does not prevent Porphyromonas gingivalis-induced alveolar bone loss in mice. Oral Microbiol Immunol 1999;14:194-196.
15. Baker PJ, Dixon M, Roopenian DC. Genetic control of susceptibility to Porphyromonas gingivalis-induced alveolar bone loss in mice. Infect Immun 2000;68:5864-5868.
16. Okamoto M, Hasegawa N, Maeda N, Sugawara N, Fujita H. Efffects of bisphosphonate on growth of Porphyromonas gingivalis. J Dent Res 1996;75(Spec. Issue): 429(Abstr. 3293).
17. Felix R, Bettex JD, Fleisch H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 1981;33:549-552.
18. Nakaya H, Osawa G, Iwasaki N, Cochran DL, Kamoi K, Oates TW. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol 2000;71:1158-1166.
19. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453-465.
20. Teronen O, Konttinen YT, Lindqvist C, et al. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 1997;76:1529-1537.
21. Teronen O, Konttinen YT, Lindqvist C. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int 1997;61:59-61.
22. Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 1998;63:325-330.
23. Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S, Kawashima H. YM175, a new bisphosphonate, increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity. Biochem Biophys Res Commun 1991;180:1172-1178.
24. Motoie H, Kanoh H, Ogata S, Kawamuki K, Shikama H, Fujikura T. Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction. Jpn J Pharmacol 1996;71:239-246.
25. Motoie H, Nakamura T, O'uchi N, et al. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 1995;10:910-920.
26. Michael WR, King WR, Wakim JM. Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972;21:503-515.
27. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-396.